COGT
HealthcareCogent Biosciences, Inc. · Biotechnology · $6B
What is Cogent Biosciences, Inc.?
Cogent Biosciences is a clinical-stage biotechnology company focused on precision therapies for patients with genetically defined diseases. Its work centers on a specific mutation that drives rare and difficult-to-treat conditions.
Cogent Biosciences develops targeted therapies designed to block the KIT D816V mutation, which drives systemic mastocytosis — a rare mast cell disorder. Its lead candidate, bezuclastinib (CGT9486), also targets KIT exon 17 mutations found in certain advanced gastrointestinal stromal tumor patients. The company operates under a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Revenue is not yet generated from product sales, as the company remains in the clinical development stage.
Cogent Biosciences was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Bezuclastinib (CGT9486) — selective KIT D816V inhibitor for systemic mastocytosis
- KIT exon 17 inhibition program for advanced gastrointestinal stromal tumors
- Precision oncology pipeline targeting genetically defined patient populations
- Licensing and development collaboration with Plexxikon Inc.
Is COGT a Good Stock to Buy?
UQS Score rates COGT as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue biotechnology companies.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet or near-term financial structure carries less immediate danger than some clinical-stage peers. This is a meaningful consideration for investors evaluating runway and dilution risk.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products, no recurring revenue, and a competitive landscape where differentiation remains unproven. Valuation is rated Elevated, meaning the market may already be pricing in optimistic pipeline outcomes.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does COGT pay dividends?
No — Cogent Biosciences, Inc. does not currently pay a dividend.
Cogent Biosciences does not pay a dividend. As a clinical-stage biotech, the company directs all available capital toward research, clinical trials, and pipeline development. This is standard practice for pre-revenue biotechnology companies, where preserving cash for operations takes priority over returning capital to shareholders.
When does COGT report earnings?
Cogent Biosciences reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash position, operating expenses, and clinical trial progress rather than traditional revenue and profit metrics. Pipeline milestones and trial readouts tend to drive more market attention than the earnings figures themselves.
For the most recent quarter's results and clinical updates, visit Cogent Biosciences' investor relations page directly.
COGT Price History
+324.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Cogent Biosciences, Inc.?
Based on Cogent Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
COGT Long-term Outlook
The fundamental outlook for Cogent Biosciences is shaped almost entirely by clinical trial outcomes. With Growth and Quality both rated Weak, the company's trajectory depends on whether bezuclastinib achieves regulatory milestones rather than on organic business expansion. The Good Risk rating provides some reassurance about near-term financial stability, but the Elevated Valuation label suggests the current price already reflects meaningful pipeline optimism. Investors should weigh the binary nature of clinical outcomes carefully.
Growth drivers
- Potential regulatory progress for bezuclastinib in systemic mastocytosis
- Expansion of KIT exon 17 program into gastrointestinal stromal tumors
- Growing clinical and commercial interest in precision oncology for rare diseases
Key risks
- Clinical trial failure or regulatory setbacks for the lead candidate
- Elevated valuation leaving limited margin of safety if milestones are delayed
- Ongoing cash burn and potential need for additional capital raises
COGT vs Peers
Cogent Biosciences operates in a niche segment of precision medicine, competing with other rare-disease and oncology-focused biotechs for capital, talent, and patient populations.
Rhythm focuses on rare genetic obesity disorders driven by melanocortin pathway mutations, giving it a distinct disease focus compared to Cogent's KIT mutation programs.
PTC Therapeutics has a broader rare-disease portfolio including approved commercial products, placing it at a more advanced stage of development than Cogent.
Caris Life Sciences emphasizes molecular profiling and precision diagnostics, operating more as a data-driven oncology platform than a pure drug developer.
Frequently Asked Questions
What does Cogent Biosciences do?
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its primary focus is bezuclastinib, a selective inhibitor targeting the KIT D816V mutation that drives systemic mastocytosis, as well as KIT exon 17 mutations found in certain gastrointestinal stromal tumor patients.
Does COGT pay dividends?
No, Cogent Biosciences does not pay a dividend. The company is pre-revenue and channels its capital into clinical development and research operations. Dividend payments are not typical for biotechnology companies at this stage of development.
When does COGT report earnings?
Cogent Biosciences reports on a quarterly cadence, as required for US-listed public companies. For exact dates and the most recent financial disclosures, check the investor relations section of the company's official website.
Is COGT a good stock to buy?
UQS Score rates COGT as Poor overall, reflecting weak Quality, Moat, and Growth pillar scores alongside an Elevated Valuation. The relative strength in the Risk pillar offers some reassurance, but the overall profile reflects the high uncertainty inherent in clinical-stage biotech investing. The full pillar breakdown is available to UQS Pro members.
Is COGT overvalued?
The UQS Valuation pillar for COGT is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about pipeline success. For pre-revenue biotechs, valuation is largely driven by clinical expectations rather than traditional earnings metrics.
How does COGT compare to its competitors?
Compared to peers like PTC Therapeutics, which has approved commercial products, Cogent remains at an earlier development stage. Rhythm Pharmaceuticals and Caris Life Sciences each target different disease areas and business models. COGT's differentiation lies in its specific focus on KIT mutation-driven diseases.
What is COGT's market cap bracket?
Cogent Biosciences is classified as a mid-cap company. This places it in a range that typically attracts both institutional and retail investor interest, though clinical-stage biotechs at this size can experience significant price volatility around trial readouts.
Who founded Cogent Biosciences?
Cogent Biosciences was incorporated in 2014 and was formerly known as Unum Therapeutics Inc., changing its name to Cogent Biosciences in October 2020. Founding details are publicly available through the company's SEC filings and official disclosures.
Is COGT a long-term quality investment?
As a long-term quality indicator, the UQS Score rates COGT as Poor. Weak scores across Quality, Moat, and Growth pillars reflect the challenges facing a pre-revenue company with no commercial products. Long-term quality typically requires durable earnings power and competitive advantages that have not yet been established here.
What is the main competitive advantage of Cogent Biosciences?
Cogent's potential advantage lies in its highly targeted approach to KIT D816V mutation inhibition — a mechanism with limited direct competition in systemic mastocytosis. However, the UQS Moat pillar is currently rated Weak, reflecting that this advantage remains unproven at a commercial level.
What sector does COGT belong to?
Cogent Biosciences operates in the Healthcare sector, specifically within biotechnology. It focuses on rare and genetically defined diseases, a subsegment of biotech that often carries high clinical risk but also significant unmet medical need and potential pricing power upon approval.
Is COGT a growth stock or value stock?
Based on its UQS profile, COGT does not fit neatly into either category. The Growth pillar is rated Weak due to the absence of revenue, while the Valuation pillar is Elevated — meaning the stock is priced for future success rather than current fundamentals. It is best characterized as a speculative clinical-stage biotech.
Unlock Full COGT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare COGT against sector peers side by side
- ✓See risk and valuation flags in full context
- ✓Track pipeline-stage companies across the Healthcare sector
- ✓Get the complete analyst view available to Pro members
Pro Analysis
COGT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 14.3 | 0.0 | 11.0 | 2.3 | 74.0 | 0.0 | +0.5 |
| May 9, 2026 | 13.8 | 0.0 | 11.0 | 0.0 | 74.0 | 0.0 | -0.5 |
| May 8, 2026 | 14.3 | 0.0 | 11.0 | 2.3 | 74.0 | 0.0 | +0.3 |
| Apr 22, 2026 | 14.0 | 0.0 | 11.0 | 2.3 | 72.2 | 0.0 | -0.1 |
| Apr 2, 2026 | 14.1 | 0.0 | 11.0 | 2.8 | 72.2 | 0.0 | — |
COGT — Pillar Breakdown
Quality
— 0.0/100 (25%)Cogent Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 2.3/100 (20%)Cogent Biosciences, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.0/100 (15%)Cogent Biosciences, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Cogent Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Cogent Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for COGT.
Score Composition
Financial Data
More Stock Analysis
How is the COGT UQS Score Calculated?
The UQS (Unified Quality Score) for Cogent Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Cogent Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Cogent Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.